US10737995B2ActiveUtilityA1
Nuclear receptor modulators and their use for the treatment and prevention of cancer
Assignee: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICESPriority: Jun 15, 2011Filed: Aug 21, 2018Granted: Aug 11, 2020
Est. expiryJun 15, 2031(~4.9 yrs left)· nominal 20-yr term from priority
C07C 255/56A61K 45/06A61K 31/12C07C 49/84A61P 35/00A61K 31/275C07C 205/45C07C 49/813C07C 49/80C07C 49/796A61K 2300/00
67
PatentIndex Score
0
Cited by
87
References
11
Claims
Abstract
Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I: wherein R 1 to R 5 and X 1 to X 5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.
Claims
exact text as granted — not AI-modifiedThe invention claimed is:
1. A compound, wherein the compound is one of the following:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
2. The compound of claim 1 , wherein the compound is:
3. The compound of claim 1 , wherein the compound is:
4. The compound of claim 1 , wherein the compound is:
5. The compound of claim 1 , wherein the compound is:
6. The compound of claim 1 , wherein the compound is:
7. The compound of claim 1 , wherein the compound is:
8. The compound of claim 1 , wherein the compound is:
9. The compound of claim 1 , wherein the compound is:
10. The compound of claim 1 , wherein the compound is:
11. The compound of claim 1 , wherein the compound is:Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.